EPIDERMODYSPLASIA VERRUCIFORMIS ASSOCIATED WITH LOW-RISK HPV – A CASE REPORT

  • Rebeka Vukovska University Clinic of Dermatology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Silvija Duma University Clinic of Dermatology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Vesna Pljakoska Acibadem Sistina Hospital, Skopje, North Macedonia
  • Goran Dimitrov University Clinic of Gynecology and Obstetrics, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Ivana Dohceva Karajovanov University Clinic of Dermatology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Elena Mircevska Arsovska University Clinic of Dermatology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia

Abstract

Epidermodysplasia verruciformis (EV) is a hereditary skin disorder that affects the body's ability to eliminate and protect against certain types of human papillomavirus (HPV), resulting in a higher risk of abnormal tissue growth and skin cancer. Typically, the signs and symptoms of this condition are presented during childhood and may include flat warts, macules that resemble pityriasis versicolor, or lesions resembling seborrheic keratoses. An 11-year-old female patient came for examination with viral verrucae that first appeared at the age of 4, on the forehead and hairline. The consulted dermatologist diagnosed verruca plana and proposed local treatment with a topical retinoid (adapalene), with limited efficacy. Over time, the verrucae spread to other areas and the patient received various treatments including cryotherapy, CO2 fractional laser, and several topical creams and oral medications. Due to suspicion of Epidermodysplasia Verruciformis (EV), a skin biopsy was performed. The histopathological findings suggested the presence of Epidermodysplasia verruciformis. The immunological analyses showed the presence of antibodies IgE and IgG At to Ebstein Barr Virus (EBV), and Cytomegalovirus (CMV). A DNA sample was taken from the patient with a biopsy and skin smear, which was subjected to HPV amplification in real-time PCR. Low-risk HPV types 6 and 44 were detected. High-risk HPV was not found. The patient was subsequently given 3 doses of the 9-valent HPV vaccine. Although some improvement was observed in certain areas, new verrucae appeared elsewhere. Patients with EV require frequent check-ups with dermatologists to evaluate for the development of new lesions and malignant transformation.


Keywords: Human papillomavirus (HPV), genetic dermatologic condition, autosomal recessive inheritance, cutaneous dysplasia.


https://doi.org/10.55302/JMS2361017v

References

1. Huang S, Wu JH, Lewis DJ, Rady PL, Tyring SK. A novel approach to the classification of epidermodysplasia verruciformis. Int J Dermatol. 2018 Nov;57(11):1344-1350. doi: 10.1111/ijd.14196. Epub 2018. PMID: 30156265.
2. Lazarczyk M, Pons C, Mendoza JA, Cassonnet P, Jacob Y, Favre M. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. Exp Med. 2008 J;205(1):35-42. doi: 10.1084/jem.20071311. Epub 2007 Dec 24. PMID: 18158319; PMCID: PMC2234378.
3. Imahorn E, Yüksel Z, Spoerri I, Gürel G, Imhof C, Saraçoğlu ZN, Koku Aksu AE, Rady PL, Tyring SK, Kempf W, Itin PH, Burger B. Novel TMC8 splice site mutation in epidermodysplasia verruciformis and review of HPV infections in patients with the disease. J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1722-1726. doi: 10.1111/jdv.14431. Epub 2017. PMID: 28646613.
4. James William D. et al. 2020. Andrews' Diseases of the Skin: Clinical Dermatology. Thirteenth ed. Edinburgh: Elsevier.
5. Myers DJ, Kwan E, Fillman EP. Epidermodysplasia Verruciformis. 2022 Sep 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022–. PMID: 30480937.
6. de Jong SJ, Imahorn E, Itin P, Uitto J, Orth G, Jouanguy E, Casanova JL, Burger B. Epidermodysplasia Verruciformis: Inborn Errors of Immunity to Human Beta-Papillomaviruses. Front Microbiol. 2018 Jun 12;9:1222. doi: 10.3389/fmicb.2018.01222. PMID: 29946305; PMCID: PMC6005841.
7. Pereira de Oliveira WR, Carrasco S, Neto CF, Rady P, Tyring SK. Nonspecific cell-mediated immunity in patients with epidermodysplasia verruciformis. J Dermatol. 2003 Mar;30(3):203-9. doi: 10.1111/j.134 ,8138.2003.tb00372.x. PMID: 12692356.
8. Gül U, Kiliç A, Gönül M, Cakmak SK, Bayis SS. Clinical aspects of epidermodysplasia verruciformis and review of the literature. Int J Dermatol. 2007 Oct;46(10):1069-72. doi: 10.1111/j.1365-4632.2006.03014.x. PMID: 17910717.
9. Patel T, Morrison LK, Rady P, Tyring S. Epidermodysplasia verruciformis and susceptibility to HPV. Dis Markers. 2010;29(3-4):199-206. doi: 10.3233/DMA-2010-0733. PMID: 21178278; PMCID: PMC3835378.
10. Nindl I, Gottschling M, Stockfleth E. Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers. 2007;23(4):247-59. doi: 10.1155/2007/942650. PMID: 17627060; PMCID: PMC3851066.
11. Adachi A, Kiyono T, Hayashi Y, Ohashi M, Ishibashi M. Detection of human papillomavirus (HPV) type 47 DNA in malignant lesions from epidermodysplasia verruciformis by protocols for precise typing of related HPV DNAs. J Clin Microbiol. 1996 Feb;34(2):369-75. doi: 10.1128/jcm.34.2.369-375.1996. PMID: 8789018; PMCID: PMC228800.
12. Yutsudo M, Hakura A. Human papillomavirus type 17 transcripts expressed in skin carcinoma tissue of a patient with epidermodysplasia verruciformis. Int J Cancer. 1987 May 15;39(5):586-9. doi: 10.1002/ijc.2910390507. PMID: 3032809.
13. Tanigaki T, Endo H. A case of epidermodysplasia verruciformis (Lewandowsky-Lutz, 1922) with skin cancer: histopathology of malignant cutaneous changes. Dermatologica. 1984;169(2):97-101. doi: 10.1159/000249578. PMID: 6479420.
14. de Oliveira WR, Festa Neto C, Rady PL, Tyring SK. Clinical aspects of epidermodysplasia verruciformis. J Eur Acad Dermatol Venereol. 2003;17(4):394-8. doi: 10.1046/j.1468-3083.2003.00703.x. PMID: 12834447.
15. Przybyszewska J, Zlotogorski A, Ramot Y. Re-evaluation of epidermodysplasia verruciformis: Reconciling more than 90 years of debate. J Am Acad Dermatol. 2017 Jun;76(6):1161-1175. doi: 10.1016/j.jaad.2016.12.035. Epub 2017 Feb 10. PMID: 28196644.
16. Gubinelli, E. et al. (2003) “Epidermodysplasia verruciformis with multiple mucosal carcinomas treated with pegylated interferon alfa and Acitretin,” Journal of Dermatological Treatment, 14(3), pp. 184–188. doi.10.1080
17. Lutzner MA, Blanchet-Bardon C. Epidermodysplasia verruciformis. Curr Probl Dermatol. 1985;13:164-85. doi: 10.1159/000410148. PMID: 2982549.
18. Anadolu R, Oskay T, Erdem C, Boyvat A, Terzi E, Gürgey E. Treatment of epidermodysplasia verruciformis with a combination of acitretin and interferon alfa-2a. J Am Acad Dermatol. 2001 Aug;45(2):296-9. doi: 10.1067/mjd.2001.114575. PMID: 11464195.
19. Micali G, Nasca MR, Dall'Oglio F, Musumeci ML. Cimetidine therapy for epidermodysplasia verruciformis. J Am Acad Dermatol. 2003 Feb;48(2 Suppl):S9-10. doi: 10.1067/mjd.2003.111. PMID: 12582373.
20. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000 May 3;92(9):690-8. doi: 10.1093/jnci/92.9.690. PMID: 10793105.
21. Orth G. Epidermodysplasia verruciformis. In: Salzman NP, Howley PM. The Papovaviridae: The Papillomaviruses, 1st ed. Plenum Press. 1987.
Published
2023-05-09
How to Cite
VUKOVSKA, Rebeka et al. EPIDERMODYSPLASIA VERRUCIFORMIS ASSOCIATED WITH LOW-RISK HPV – A CASE REPORT. Journal of Morphological Sciences, [S.l.], v. 6, n. 1, p. 17-23, may 2023. ISSN 2545-4706. Available at: <https://jms.mk/jms/article/view/vol6no1-3>. Date accessed: 19 may 2024.
Section
Articles